Sitemap

EU Commission Concludes Exploratory Talks With Valneva To Secure A New Potential Vaccine

CorD Recommends

Balkan Borders Blur as Free Labor Movement Pact Launches

Marking a significant shift in the labor...

Serbia Commits €5.4 Billion to Renewable Energy by 2030

Serbia's state-owned power company, Elektroprivreda Srbije (EPS),...

Serbia and Angola Cement Cultural Bonds with New Cooperation Programme

Serbia and Angola have inked a Cultural...

Serbia Awards Distinctions to Notable Personalities on National Day

In a ceremonial tribute to Serbia's National...

Putin Wins Russian Election Decisively

Presidential candidate Vladimir Putin has won 87.26 percent of the vote based on 60 percent of the ballots counted,...

Vaughan Gething to Become First Black Welsh Premier and First Black Leader in Europe

Vaughan Gething is set to make history as the first black Premier of Wales following his victory in the...

New ENEF II Fund to Propel Growth in Western Balkans

The European Bank for Reconstruction and Development (EBRD) has announced the introduction of the Enterprise Expansion Fund II (ENEF...

European Parliament Passes Groundbreaking AI Law

The European Parliament has adopted the Artificial Intelligence (AI) Act, aiming to safeguard fundamental rights, democracy, the rule of...

Mariya Gabriel Endorses Horizon Europe’s Widening Measures to Bridge Research Gap Ahead of Bulgarian Premiership

Mariya Gabriel, set to ascend to Bulgaria's prime ministerial role in March, champions Horizon Europe's Widening measures as a...

European Commission concluded exploratory talks with the pharmaceutical company Valneva with a view to purchasing its potential vaccine against COVID-19.

The envisaged contract with Valneva would provide for the possibility for all EU Member States to purchase together 30 million doses, and they could further purchase up to 30 million more doses.

Today’s finalisation of exploratory talks with Valneva come in addition to an already secured broad portfolio of vaccines to be produced in Europe, including the contracts already signed with AstraZeneca, Sanofi-GSK, Janssen Pharmaceutica NV, BioNtech-Pfizer, CureVac, and Moderna and exploratory talks concluded with Novavax. This diversified vaccines portfolio will ensure Europe is well prepared for vaccination, once the vaccines have been proven to be safe and effective, as is already the case for BioNTech/Pfizer and Moderna, recently authorised in the EU. Member States are able to donate vaccines to lower and middle-income countries or to re-direct it to other European countries.

President of the European Commission, Ursula von der Leyen, said: “The continuing COVID-19 pandemic in Europe and around the globe makes it more important than ever that all Member States have access to the broadest possible portfolio of vaccines to help protect people in Europe and beyond. Today’s step toward reaching an agreement with Valneva further complements the EU’s vaccines portfolio and demonstrates the Commission’s commitment to find a lasting solution to the pandemic.”

Stella Kyriakides, Commissioner for Health and Food Safety, said: With this eighth vaccine, we are adding to our already broad and diversified range of vaccines in our portfolio. By doing this, we can maximise our chances of making sure that all citizens can have access to safe and effective of vaccinations by the end of 2021. All Member States have now started their vaccination campaigns and will start receiving an increasing number of doses in order to cover all their needs during this year.”

Valneva is a European biotechnology company developing an inactivated virus vaccine. This is a traditional vaccine technology, used for 60-70 years, with established methods and a high level of safety. Most of the influenza vaccines and many childhood vaccines use this technology. This is currently the only inactivated vaccine candidate in clinical trials against COVID-19 in Europe.

The Commission, with the support of EU Member States, has taken a decision to support this vaccine based on a sound scientific assessment, the technology used, the company’s experience in vaccine development and its production capacity to supply all EU Member States.

Related Articles

New ENEF II Fund to Propel Growth in Western Balkans

The European Bank for Reconstruction and Development (EBRD) has announced the introduction of the Enterprise Expansion Fund II (ENEF II), aimed at fostering the...

European Parliament Passes Groundbreaking AI Law

The European Parliament has adopted the Artificial Intelligence (AI) Act, aiming to safeguard fundamental rights, democracy, the rule of law, and ecological sustainability in...

Mariya Gabriel Endorses Horizon Europe’s Widening Measures to Bridge Research Gap Ahead of Bulgarian Premiership

Mariya Gabriel, set to ascend to Bulgaria's prime ministerial role in March, champions Horizon Europe's Widening measures as a key strategy to address Europe's...

European Parliament Members Endorse Western Balkan Reform and Growth Instrument

Members of the European Parliament's committees on foreign affairs and budget have officially adopted a stance on the Western Balkan Reform and Growth Instrument,...

EU Inaugurates Central Office for Artificial Intelligence

The European Union has taken a significant step forward in the realm of artificial intelligence by inaugurating its Artificial Intelligence Office. This central body...

European Banking Titans Surpass €100 Billion Profit Milestone Amid Rising Interest Rates

For the first time in history, Europe's banking behemoths have collectively breached the €100 billion profit ceiling, fueled by a significant uptick in interest...

Western Balkans Eye EU Membership by 2028

At the esteemed Munich Security Conference, a cornerstone event in global security discourse, leaders from North Macedonia, Albania, and Montenegro have passionately renewed their...

EIB Global Channels Record €1.2 Billion into Western Balkans

EIB Global, the European Investment Bank's arm for non-EU activities, has made a landmark investment of €1.2 billion in the Western Balkans for 2023,...